Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chip-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2

ABSTRACT: Chip-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2

PROVIDER: PRJNA810496 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18148044_1.fastq.gz	Fastqsanger.gz
	SRR18148044_2.fastq.gz	Fastqsanger.gz
	SRR18148045_1.fastq.gz	Fastqsanger.gz
	SRR18148045_2.fastq.gz	Fastqsanger.gz
	SRR18148046_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

RNA-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2 and H929

Project description:RNA-seq analysis after dBRD9-A treatment in human multiple myeloma cell line OPM2 and H929

| PRJNA810495 | ENA

Effect of forkhead box M1 in multiple myeloma

Project description:Forkhead Box M1 (FOXM1) is a promising molecular target for high-risk multiple myeloma and relapse and refractory myeloma, but whether FOXM1 is essential in myeloma has not yet been established. To address this knowledge gap, we used Western blotting to measure FOXM1 protein levels in 11 human myeloma cell lines (HMCLs) and then chose the two lines expressing the largest amount of the transcription factor, OPM2 and Delta47, for gene editing using CRISPR-Cas9. In both cases, two independent FOXM1-deficient daughter lines, designated KO-1 and KO-2, were generated. They contained 2 different 10-bp deletions at the target site of their respective guide RNA in case of OPM2 and a 10-bp deletion and 1-bp insertion in case of Delta47. Western analysis confirmed the lack of FOXM1 in all knockout clones. FOXM1-deficient myeloma cells proliferated more slowly than their parental counterparts containing normal levels of FOXM1. Moreover, we added back FOXM1 to FOXM1-KO cells by transfection of a constitutively expressed FOXM1c cDNA gene. The reconstituted OPM2 and Delta47 cells, designated FOXM1 KO-R contained high amounts of FOXM1 protein. Here, we used these cell lines to investigate the role of FOXM1 in regulating the gene expression in multiple myeloma.

2021-07-14 | GSE180018 | GEO

Effect of treatment OPM2 multiple myeloma cells with EPA, DHA or bortezomib

Project description:Effect of treatment OPM2 multiple myeloma cells with EPA, DHA or bortezomib

| PRJEB54097 | ENA

Gene Expression Profiles of Multiple Myeloma Before Treatment

Project description:Samples in this series are pre-treatment bone marrow aspirates from multiple myeloma patients Keywords = CKS1B in Multiple Myeloma, Bone Marrow, Pre-Treatment Keywords: other

2006-06-01 | GSE4204 | GEO

Huma Multiple Myeloma Cell line, AMO1, treated with NCP26, LC-MSMS analysis

Project description:The human multiple myeloma cell line, AMO1, was treated with NCP26, an ATP-competitive EPRS inhibitor, and a total proteome-wide analysis was performed to determine the effect of NCP26 treatment on protein dynamics.

2023-03-11 | PXD029453 | Pride

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA

Gene Expression Profiling of OPM2 treatment with VS-5584 (SB2343).

Project description:The PI3K/mTOR pathway is a constitutively active in multiple myeloma. Single inhibition of mTOR usually confers reactivation of the pathway. VS-5584 (SB2343) is a bispecific PI3K/mTOR inhibitor which effectively and specifically inhibits the target pathways and shows potent anti-myeloma activity. We utilised a gene microarray analysis to analyse and identify the genes that were sensitively regulated by VS-5584 treatment in OPM2. OPM2 cells were either treated with DMSO(drug solvent) or with 125nM of VS-5584(SB2343) which is half the IC50 concentration of the drug at 48h in OPM2 cells. The cells were harvested at 24h in order to detect the regulation of relatively early response genes.

2016-07-27 | E-GEOD-84862 | biostudies-arrayexpress

RNA-seq analysis after JQKD82 treatment in human multiple myeloma cell line MM.1S

Project description:RNA-seq analysis after JQKD82 treatment in human multiple myeloma cell line MM.1S

| PRJNA622959 | ENA

Multiple Myeloma cells

Project description:Multiple Myeloma cells

| PRJNA800411 | ENA

Multiple Myeloma cells

Project description:Multiple Myeloma cell line MM.1S performed ChIP-seq analysis using anti-c-Fos antibody.

2022-01-30 | GSE194381 | GEO